Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 4/20 | 0.50 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL718881 | 0.91 | KMT2A (0.52) | DGAT1MAPTALDH1A1KMT2AMEN1 | |
| SCHEMBL12265096 | 0.84 | MAPT (0.64) | MAPTALDH1A1KMT2AMEN1L3MBTL1 | |
| SCHEMBL718353 | 0.81 | KMT2A (0.52) | MAPTALDH1A1KMT2AMEN1L3MBTL1 | |
| SCHEMBL720432 | 0.80 | L3MBTL1 (0.58) | MAPTALDH1A1KMT2AMEN1L3MBTL1 | |
| SCHEMBL718451 | 0.77 | NOTUM (0.59) | DGAT1NOTUMMAPTALDH1A1KMT2A | |
| SCHEMBL14905660 | 0.77 | MAPT (0.42) | MAPTALDH1A1KMT2AMEN1L3MBTL1 | |
| SCHEMBL719353 | 0.76 | NOTUM (0.48) | DGAT1NOTUMMAPTALDH1A1KMT2A | |
| SCHEMBL718941 | 0.74 | ALDH1A1 (0.55) | NOTUMMAPTALDH1A1KMT2AMEN1 | |
| SCHEMBL717912 | 0.74 | MAPT (0.45) | DGAT1MAPTALDH1A1KMT2AMEN1 | |
| SCHEMBL717852 | 0.74 | MAPT (0.64) | MAPTALDH1A1KMT2AMEN1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436043-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-07 | — | — | US | disclosed |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-25 | — | — | US | disclosed |
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
| EP-2251326-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | DGAT1 869/4885NOTUM 1954/4885MAPT 4533/4885 |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | DGAT1 869/4885NOTUM 1954/4885MAPT 4533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.